Asymmetric synthesis of a potent, aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV inhibitor. 2010

Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
Department of Process Research, Merck Research Laboratory, Rahway, New Jersey 07065, USA. feng_xu@merck.com

A practical asymmetric synthesis of a novel aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV (DPP-4) inhibitor 1 has been developed. Application of a unique three-component cascade coupling with chiral nitro diester 7, which is easily accessed via a highly enantioselective Michael addition of dimethyl malonate to a nitrostyrene, allows for the assembly of the functionalized piperidinone skeleton in one pot. Through a base-catalyzed, dynamic crystallization-driven process, the cis-piperidionone 16a is epimerized to the desired trans isomer 16b, which is directly crystallized from the crude reaction stream in high yield and purity. Isomerization of the allylamide 16b in the presence of RhCl(3) is achieved without any epimerization of the acid/base labile stereogenic center adjacent to the nitro group on the piperidinone ring, while the undesired enamine intermediate is consumed to <0.5% by utilizing a trace amount of HCl generated from RhCl(3). The amino lactam 4, obtained through hydrogenation and hydrolysis, is isolated as its crystalline pTSA salt from the reaction solution directly, as such intramolecular transamidation has been dramatically suppressed via kinetic control. Finally, a Cu(I) catalyzed coupling-cyclization allows for the formation of the tricyclic structure of the potent DPP-4 inhibitor 1. The synthesis, which is suitable for large scale preparation, is accomplished in 23% overall yield.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010881 Piperidones A family of saturated heterocyclic organic compounds which contain one nitrogen atom and a carbonyl group in the ring structure. Piperidone
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D006575 Heterocyclic Compounds, 3-Ring A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category. Fused Heterocyclic Compounds, Three-Ring,Heterocyclic Cpds, 3 Ring,Three Ring Heterocyclic Compounds,3-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Three Ring,Heterocyclic Compounds, 3 Ring
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D054873 Dipeptidyl-Peptidase IV Inhibitors Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. DPP-4 Inhibitor,DPP-4 Inhibitors,DPP-IV Inhibitor,DPP-IV Inhibitors,DPP4 Inhibitor,DPP4 Inhibitors,Dipeptidyl Peptidase 4 Inhibitor,Dipeptidyl-Peptidase 4 Inhibitor,Dipeptidyl-Peptidase IV Inhibitor,Gliptin,Gliptins,Dipeptidyl-Peptidase 4 Inhibitors,DPP 4 Inhibitor,DPP 4 Inhibitors,DPP IV Inhibitor,DPP IV Inhibitors,Dipeptidyl Peptidase 4 Inhibitors,Dipeptidyl Peptidase IV Inhibitor,Dipeptidyl Peptidase IV Inhibitors,Inhibitor, DPP-4,Inhibitor, DPP-IV,Inhibitor, DPP4,Inhibitor, Dipeptidyl-Peptidase 4,Inhibitor, Dipeptidyl-Peptidase IV
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
August 2009, Bioorganic & medicinal chemistry letters,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
June 1998, Bioorganic & medicinal chemistry letters,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
September 2001, The Journal of antibiotics,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
May 2007, Journal of medicinal chemistry,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
January 2012, Dermatology (Basel, Switzerland),
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
December 2015, Journal of enzyme inhibition and medicinal chemistry,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
December 2006, Bioorganic & medicinal chemistry letters,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
December 2007, Bioorganic & medicinal chemistry letters,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
September 2005, Bioorganic & medicinal chemistry letters,
Feng Xu, and Edward Corley, and Michael Zacuto, and David A Conlon, and Brenda Pipik, and Guy Humphrey, and Jerry Murry, and David Tschaen
February 2012, The Australasian journal of dermatology,
Copied contents to your clipboard!